On Thursday, 35 US states and the District of Colombia filed a lawsuit again the the opioid maker Indivior, alleging that the company tried to keep generic versions of a drug off the market.
Indivior makes Suboxone, a drug used to treat heroine addicts and addicts of other painkillers.
According to the lawsuit by the states, Indivior told the FDA that it planned to offer a new “sublingual film,” or dissolvable strip version of the drug, which had been licensed to Indivior by MonoSol.
Since the strip was not equivalent to the tablet version of the drug, it would prevent pharmacists from prescribing a cheaper generic alternative to patients.
The lawsuit claims that the company persuaded the FDA to approve the strip by raising concerns that the tablet posed high exposure risks to children. It later used those pediatric safety claims again to try to persuade the FDA not to approve generic tablets of Suboxone.
The complaint alleges that although the FDA rejected the company’s arguments, by the time the generics hit the marketplace, many patients had already switched over to using the dissolvable strip. There is currently no generic version of the dissolvable strip.
Full Content: CNBC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Massachusetts AG Sues Insulin Makers and PBMs Over Alleged Price-Fixing Scheme
Jan 14, 2025 by
CPI
Apple and Amazon Avoid Mass Lawsuit in UK Over Alleged Collusion
Jan 14, 2025 by
CPI
Top Agent Network Drops Antitrust Suit Against National Association of Realtors
Jan 14, 2025 by
CPI
Weil, Gotshal & Manges Strengthens Antitrust Practice with New Partner
Jan 14, 2025 by
CPI
Russian Court Imposes Hefty Fine on Google for Non-Compliance with Content Removal Orders
Jan 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand